Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best income stocks. Amid ...

A major driver of this success was the positive outcome of the MIRASOL trial, where Elahere showed a clear advantage over chemotherapy in treating ovarian cancer, cutting the risk of death by 32% ...

Ovarian Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted ovarian cancer epidemiology in the 7MM, i.e., the United States ...

Elahere emerged as the crown jewel of AbbVie’s oncology pipeline. Thanks to the MIRASOL trial, it proved to be significantly more effective than chemotherapy in treating ovarian cancer. With a 32% ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence ...

AbbVie’s oncology/hematology sales rose 7.5% to $1.63 billion in the quarter, as sales from the recently acquired ovarian cancer drug Elahere and rising Venclexta sales more than offset the ...

Medscape Medical News, October 11, 2024 Alert EMA Backs Approval of Elahere for Ovarian Cancer Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant ...

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski ...

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data. Medical affairs is evolving. Once primarily viewed as a support function in healthcare ...